Pulmatrix
PULM · Nasdaq · United States
Share price · PULM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PULM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+14.3%
Nothing announced by PULM that day or the session before.
- 22 Oct 2026-9.6%
Nothing announced by PULM that day or the session before.
- 21 Oct 2026+9.8%
Nothing announced by PULM that day or the session before.
- 21 Sep 2026+16.7%
Nothing announced by PULM that day or the session before.
- 9 Sep 2026+6.1%
Nothing announced by PULM that day or the session before.
- 8 Jul 2026+8.7%
Nothing announced by PULM that day or the session before.
- 25 Jun 2026+9.2%
Nothing announced by PULM that day or the session before.
- 26 Mar 2026-28.8%
- 20 Mar 2026+15.8%
Nothing announced by PULM that day or the session before.
- 2 Mar 2026-36.8%
Share of unusual movement by asset
For each asset, the share of PULM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Itraconazole (PUR1900)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 49% |
| Sessions with no dated event | — | 51% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | fungal CYP51 (lanosterol 14α-demethylase)Small molecule | Allergic Bronchopulmonary Aspergillosis | |
PUR1800No recent activity | Phase 1 | Narrow-spectrum kinase (p38/Syk-family)Small molecule | Chronic Obstructive Pulmonary Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $0 | $2.2M | $1.0M-$1.1M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $0 | $3.3M | $1.2M-$1.1M operating cash flow | report ↗ |
| 2025-Q3 | — | <$0.1M | $4.8M | $0.9M-$1.0M operating cash flow | report ↗ |
| 2025-Q2 | — | <$0.1M | $5.8M | $1.6M-$1.9M operating cash flow | report ↗ |
| 2025-Q1 | — | <$0.1M | $7.7M | $1.8M-$1.8M operating cash flow | report ↗ |
| 2024-Q3 | $0.4M | $0.8M | $11M | $2.6M-$3.1M operating cash flow | report ↗ |
| 2024-Q2 | $1.6M | $2.8M | $12M | $5.8M-$3.7M operating cash flow | report ↗ |
| 2024-Q1 | $5.9M | $3.5M | $16M | —-$2.7M operating cash flow | report ↗ |
| 2023-Q3 | $1.8M | $4.0M | $21M | $3.8M-$4.1M operating cash flow | report ↗ |
| 2023-Q2 | $1.8M | $4.2M | $26M | $3.8M-$4.9M operating cash flow | report ↗ |
| 2023-Q1 | $1.5M | $3.9M | $31M | $4.5M-$4.9M operating cash flow | report ↗ |
| 2022-Q3 | $1.9M | $5.3M | $41M | $5.0M-$3.6M operating cash flow | report ↗ |
| 2022-Q2 | $1.3M | $4.3M | $43M | $4.6M-$4.6M operating cash flow | report ↗ |
| 2022-Q1 | $1.2M | $4.2M | $48M | $5.0M-$6.1M operating cash flow | report ↗ |
| 2021-Q3 | $1.1M | $4.0M | $53M | $8.2M-$3.3M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | <$0.1M | $4.1M | $1.3M-$5.4M operating cash flow | report ↗ |
Pulmatrix reported revenue of nil for fiscal 2025, versus $7.81M in 2024, with the 2024 revenue primarily tied to the Cipla PUR1900 agreement. R&D spend was $0.04M, down 99.4% YoY, and cash and equivalents were $4.09M as of December 31, 2025. The company recorded a net loss of $5.16M.
Management said the current cash position is expected to fund operations into the first quarter of 2027. The company continues to pursue its proposed merger with Cullgen, with CSRC approval among remaining closing conditions, and both parties have waived the No Solicitation clause to explore alternative transactions. Pulmatrix is also seeking to license or monetize its iSPERSE technology and related clinical programs, including Phase 2-ready PUR3100 for acute migraine, PUR1800 for AECOPD, and PUR1900, which its partner Cipla has been approved to advance to Phase 3 in India.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $7.8M | $7.2M | $9.5M | $2.4M-$11M operating cash flow | report ↗ |
| 2023-FY | $7.3M | $16M | $19M | $3.5M-$16M operating cash flow | report ↗ |
| 2022-FY | $6.1M | $18M | $36M | $4.7M-$19M operating cash flow | report ↗ |
| 2021-FY | $5.2M | $15M | $54M | $5.0M-$20M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-02-03 | Higgins Michael J · director | Award / grant (derivative) | 8,800 | — | — | Form 4 |
| 2023-01-26 | Batycky Richard P. · director | Award / grant (derivative) | 1,700 | — | — | Form 4 |
| 2023-01-26 | Varadan Anand · director | Award / grant (derivative) | 1,700 | — | — | Form 4 |
| 2023-01-26 | Cabell Christopher · director | Award / grant (derivative) | 1,700 | — | — | Form 4 |
| 2023-01-26 | Higgins Michael J · director | Award / grant (derivative) | 2,436 | — | — | Form 4 |
| 2023-01-26 | Bazemore Todd · director | Award / grant (derivative) | 1,700 | — | — | Form 4 |
| 2023-01-26 | Raad Teofilo David · director, Chief Executive Officer | Award / grant (derivative) | 34,900 | — | — | Form 4 |
| 2023-01-26 | Wasilewski Margaret · Chief Medical Officer | Award / grant (derivative) | 11,400 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 15 reporting institutions held 0.3M shares ($425K, 9.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 109,148 | $141K |
| 2 | BlackRock, Inc. | 54,899 | $71K |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 44,629 | $58K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 33,594 | $43K |
| 5 | SBI Securities Co., Ltd. | 30,085 | $39K |
| 6 | VANGUARD FIDUCIARY TRUST CO | 14,715 | $19K |
| 7 | JANE STREET GROUP, LLC | 14,584 | $19K |
| 8 | STATE STREET CORP | 13,945 | $18K |
| 9 | XTX Topco Ltd | 13,669 | $18K |
| 10 | Tower Research Capital LLC (TRC) | 207 | $267 |
| 11 | UBS Group AG | 23 | $30 |
| 12 | Farther Finance Advisors, LLC | 7 | $9 |
| 13 | Allworth Financial LP | 3 | $4 |
| 14 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 1 | $1 |
| 15 | ROYAL BANK OF CANADA | 7 | $0 |